Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Next Previous
Search
Drug Profile

Research programme: CID based cellular immunotherapies - Bellicum Pharmaceuticals

Alternative Names: BCMA GoCAR-NK - Bellicum Pharmaceuticals; BPX 401; BPX 602; BPX-802; BPZ-2003; CaspaCIDe-enabled CD19 CAR; CaspaCIDe® T Cell immunotherapies - Bellicum Pharmaceuticals; Chemical Induction of Dimerization enabled cellular immunotherapies - Bellicum Pharmaceuticals; CIDeCar#1; DeCIDe® based immunotherapies - Bellicum pharmaceuticals; DS GoCAR-T cells - Bellicum Pharmaceuticals; Dual-Switch CAR-T Cells; Dual-switch GoCAR-T cells - Bellicum Pharmaceuticals; GoCAR-T based immunotherapies - Bellicum Pharmaceuticals

Latest Information Update: 05 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Feb 2024 Discontinued - Preclinical for Haematological malignancies in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
  • 23 Feb 2024 Discontinued - Preclinical for Solid tumours in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
  • 05 Dec 2020 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top